NICM
SRNE

Neo Ivy Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Neo Ivy Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,668
Closed -$65K – 675
2021
Q2 		$65K Buy
+6,668
New +$53.1K 0.07% 297
2020
Q4 		– Sell
-196
Closed -$2K – 623
2020
Q3 		$2K Buy
+196
New +$1.79K ﹤0.01% 443

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Neo Ivy Capital Management's SRNE Position: Q3 2021 in Review

Neo Ivy Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2021, closing a stake of 6,668 shares — an estimated $65K sold.

Neo Ivy Capital Management first reported a position in SRNE in Q3 2020 and held it in 2 quarters. The position peaked at $65K in Q2 2021. 220 funds tracked by Wall St. Rank hold SRNE as of Q3 2021.

  • Neo Ivy Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
  • Neo Ivy Capital Management sold 6,668 Sorrento Therapeutics, Inc. shares in Q3 2021, an estimated $65K.
  • Neo Ivy Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 2 quarters.
  • Neo Ivy Capital Management's Sorrento Therapeutics, Inc. position peaked at $65K in Q2 2021.
  • 220 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2021.

Based on Neo Ivy Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.